Balyasny Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Balyasny Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-833	Closed	-$287K	–	1569
2019 Q3	$287K	Buy	+833	New	+$453K	﹤0.01%	1023
2019 Q2	–	Sell	-370	Closed	-$590K	–	1801
2019 Q1	$590K	Sell	370 -2,376	-87%	-$4.28M	﹤0.01%	1164
2018 Q4	$5.13M	Buy	2,746 +2,563	+1,401%	+$5.58M	0.04%	503
2018 Q3	$431K	Buy	+183	New	+$566K	﹤0.01%	1420
2018 Q2	–	Sell	-106	Closed	-$300K	–	2246
2018 Q1	$300K	Sell	106 -31	-23%	-$92.8K	﹤0.01%	1614
2017 Q4	$352K	Buy	+137	New	+$389K	﹤0.01%	1676
2016 Q1	–	Sell	-1,443	Closed	-$7.41M	–	1593
2015 Q4	$7.41M	Sell	1,443 -677	-32%	-$2.96M	0.05%	422
2015 Q3	$6.74M	Buy	2,120 +1,174	+124%	+$4.55M	0.05%	440
2015 Q2	$3.79M	Buy	+946	New	+$3.65M	0.02%	660
2014 Q4	–	Sell	-1,077	Closed	-$4.38M	–	881
2014 Q3	$4.38M	Buy	+1,077	New	+$4.04M	0.03%	482

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Balyasny Asset Management's ACOR Position: Q4 2019 in Review

Balyasny Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 833 shares — an estimated $287K sold.

Balyasny Asset Management first reported a position in ACOR in Q3 2014 and held it in 10 quarters. The position peaked at $7.41M in Q4 2015. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

Balyasny Asset Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
Balyasny Asset Management sold 833 Acorda Therapeutics shares in Q4 2019, an estimated $287K.
Balyasny Asset Management first reported a position in Acorda Therapeutics in Q3 2014 and held it in 10 quarters.
Balyasny Asset Management's Acorda Therapeutics position peaked at $7.41M in Q4 2015.
121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Balyasny Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.